Blueprint Medicines Wins First FDA Approval

Posted by ISPE Boston
On January 22, 2020

Blueprint Medicines, a Cambridge biotech focused on genomically defined cancers, rare diseases and cancer immunotherapy, has announced FDA approval for Ayvakit (avapritinib), its kinase inhibitor for the treatment of a genomically defined population of patients with gastrointestinal stromal tumor (GIST), a rare, sarcoma of the GI tract. “The full approval of Ayvakit…is an incredibly exciting […]

Sarepta & Roche Ink $1.1b Licensing Deal

Posted by ISPE Boston
On January 10, 2020

Sarepta Therapeutics and Roche have entered into a licensing agreement providing Roche exclusive commercial rights to SRP-9001, Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the United States. Under the agreement, Sarepta will receive $1.15 billion in an upfront payment and an equity investment; up to $1.7 billion in regulatory and sales milestones; […]

Ring Therapeutics to Use Novel Viruses to Deliver Gene Therapies

Posted by ISPE Boston
On January 10, 2020

Flagship Pioneering has launched Ring Therapeutics, an early-stage biotech developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring’s technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk […]

Chapter Member Anniversaries: January 2020

Posted by ISPE Boston
On January 3, 2020

Please congratulate the following members celebrating milestone anniversaries in January 2020. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Daniel E. Baxter, Vertex Pharmaceuticals Incorporated Dr. Anthony C. Bevilacqua, Ph.D., Mettler-Toledo Thornton Inc Erik M. Caldwell, Northeast Water Svcs, Inc. Brian L. Clark, GMP Operations Consulting Andrew […]

Welcome New Members!

Posted by ISPE Boston
On January 3, 2020

We would like to introduce the Members who joined ISPE in December 2019, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

Sarepta Wins FDA Approval for Vyondys for Duchenne Muscular Dystrophy

Posted by ISPE Boston
On December 19, 2019

The FDA has approved Sarepta Therapeutics’ Vyondys 53 (golodirsen), an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 53 skipping. Vyondys 53 is approved under accelerated review based on an increase in dystrophin production in skeletal muscle of patients […]

Cambridge Start-Up Launches with $59 Million in Financing

Posted by ISPE Boston
On December 19, 2019

Triplet Therapeutics has launched today with $59 million in financing including a $49 million Series A financing led by MPM Capital and Pfizer Ventures U.S. LLC, the venture capital arm of Pfizer. Atlas Venture, which co-founded and seeded Triplet with a $10 million investment, also participated in the Series A alongside Invus, Partners Innovation Fund and […]

A Shout-Out from Apple Watch Winner

Posted by ISPE Boston
On December 19, 2019

Student member and Apple Watch winner Jena LaMontagna is on her way to a BS in Chemical Engineering with a minor in Biochemical Engineering at Northeastern University. To help celebrate her win, she shared a few thoughts about ISPE. How did you learn about ISPE? I first learned about ISPE through my university and later […]

ArQule to be Acquired by Merck

Posted by ISPE Boston
On December 12, 2019

Merck will acquire Burlington-based ArQule for $20 per share in cash for a total equity value of about $2.7 billion. The transaction is expected to close early in the first quarter of 2020. ArQule is a publicly-traded biopharma focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. […]

Chapter Member Anniversaries: December 2019

Posted by ISPE Boston
On December 9, 2019

Please congratulate the following members celebrating milestone anniversaries in December 2019. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Michelle D. Bailey, Vertex Pharmaceuticals Judith R. Bodette, DPS Group Jack G. Campion, P.E., The Hart Companies Carl J. Carlson, Exyte Thomas R. Choyce, PE, Biogen George A. […]

Page 63 of 90«‹61 626364 65 ›»